Renal Cancer: Sequencing Panel
Test Code: 9796
Turnaround time: 5 weeks
Renal cancer is a multifarious and heterogeneous disease with a varied spectrum of malignant subtypes and clinical presentation. A number of gene mutations have been reported in the literature. Renal cell carcinoma (RCC) tumor subtypes include clear cell or conventional (70-80%); papillary type 1 and type 2 (10-15%); chromophobe (3-5%) and collecting duct (1%). The general population’s lifetime risk to develop RCC is 1.5%. RCC is the seventh and eighth most common cancer in men and women respectively. Approximately 3-5% of RCC cases are hereditary and occur as a result of an inherited mutation. Unlike sporadic RCC cases, hereditary RCC is often categorized by earlier disease onset and/or multifocal or bilateral tumors.
- Altekruse, S., et al. (2009). Seer cancer statistics review, 1975-2007, National Cancer Institute. http://seer.cancer.gov/statfacts/html/kidrp.html#risks. Accessed June 13, 2013.
- Rini, B., et al. (2006). Renal cell carcinoma. Curr Opin in Onc, 18(3):289-296.
- Rosner, I., et al. (2009). The clinical implications of the genetics of renal cell carcinoma. Urologic Oncology, 27(2):131-136.
- Coleman, J., and Russo, P. (2009). Hereditary and familial kidney cancer. Curr Opin Urol, 19:478-485.
BAP1, BUB1B, CDC73, CDKN1C, FH, FLCN, GPC3, MET, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, SDHB, SDHD, SDHC, SMARCB1, TP53, TSC1, TSC2VHL, WT1
The test is indicated for:
- Individuals with a clinical or suspected diagnosis of renal cancer.
Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient’s genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not mean to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient’s gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.
Next Generation Sequencing: Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions/duplications will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient’s clinical/biochemical phenotype.
Analytical Sensitivity: ~99%.
Submit only 1 of the following specimen types
Type: Whole Blood
Specimen Requirements: In EDTA (purple top) tube: Infants (2 years): 3-5 ml
Older Children & Adults: 5-10 ml.
Specimen Collection and Shipping: Ship sample at room temperature with overnight delivery.
Type: Isolated DNA
Specimen Requirements: In microtainer: 60 μg
Isolation using the QiagenTM Puregene kit for DNA extraction is recommended.
Specimen Collection and Shipping: Refrigerate until time of shipment in 100 ng/ul of TE buffer. Ship sample at room temperature with overnight delivery.
This test is for germline mutation analysis. DNA isolated from FFPE tumor samples is not suitable for this test.
- Hereditary Cancer Syndrome: Sequencing Panel.
- Renal Cancer: Deletion/Duplication Panel.